Contrast-enhanced MRI for quantification of myocardial viability.
During the past 10 years substantial advances have taken place in magnetic resonance imaging (MRI) capabilities and in contrast media development. Furthermore, knowledge of in vivo contrast media interactions with surrounding water and distribution into tissue has increased, permitting regional quantification of concentration-time profiles in the myocardium. The combination of these advances has substantially improved the capability of contrast-enhanced MRI characterization of myocardial ischemic injury, including its ability to discriminate viable from nonviable zones. Discrimination of viable from nonviable myocardial subregions is important for patient management and for research applications. This review addresses recent progress toward the goal of defining viable and nonviable myocardium based on MRI detection of contrast media effects. J. Magn. Reson. Imaging 1999;10:694-702.
Wendland
M F
MF
Department of Radiology, University of California, San Francisco, California 94143-0628, USA. mike.wendland@radiology.ucsf.edu
Saeed
M
M
Lund
G
G
Higgins
C B
CB
D000818:Animals; D003287:Contrast Media; D004419:Dysprosium; D004492:Edetic Acid / Q000031:analogs & derivatives; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008345:Manganese; D017202:Myocardial Ischemia / Q000175:diagnosis*; D017682:Myocardial Stunning / Q000175:diagnosis*; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives
D003287:Contrast Media; D009942:Organometallic Compounds; C061756:sprodiamide; D004419:Dysprosium; D008345:Manganese; D011732:Pyridoxal Phosphate; D004369:Pentetic Acid; D004492:Edetic Acid; D019786:Gadolinium DTPA; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid